We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves First Duchenne Treatment, Sarepta’s Exondys 51
FDA Approves First Duchenne Treatment, Sarepta’s Exondys 51
The FDA granted accelerated approval to Sarepta’s Exondys 51—the first drug indicated for the treatment of Duchenne muscular dystrophy—despite reservation from FDA staff and an advisory panel.